Citation Impact
Citing Papers
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
2013
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Single-Cell Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation
2019
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
2014
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice
2010
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
2019
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Cancer/testis (CT) antigens: Potential targets for immunotherapy
2009
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Combining immunotherapy and targeted therapies in cancer treatment
2012
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
2010
The biology and management of non-small cell lung cancer
2018 StandoutNature
Deciphering and Reversing Tumor Immune Suppression
2013
Immunological off-target effects of imatinib
2016
Regulatory T Cells in Cancer
2010
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
The immune contexture in cancer prognosis and treatment
2017 Standout
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
2015
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Basic principles of tumor-associated regulatory T cell biology
2012
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
2013
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
2023
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2017 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Gastric cancer
2020 Standout
<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
2016
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
2015
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
The secret ally: immunostimulation by anticancer drugs
2012
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases
2020 StandoutNobel
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
2016
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The significant role of mast cells in cancer
2011
Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)
2015
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Pancreatic cancer
2011 Standout
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008
Hepatocellular Carcinoma
2019 Standout
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
2011
Inferring tumour purity and stromal and immune cell admixture from expression data
2013 Standout
Roles of regulatory T cells in cancer immunity
2016
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 high regulatory T cells in humans
2015 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70
2013
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes
2013 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Dirk Jaeger being referenced
Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
2011
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma
2009
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue
2013
Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
2008
Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration
2013
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
2022
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
2018
Surgery for Recurrent Pancreatic Ductal Adenocarcinoma
2007
Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine
2013
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
2015
First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
2015
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
2016
A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01).
2014
Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer
2004
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
2017
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.
2015